alexa Metal-Based Compounds as Proteasome-Inhibitory Anti Cancer Drugs

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Metal-Based Compounds as Proteasome-Inhibitory Anti Cancer Drugs

Since the war on cancer began forty years ago, significant advances have been made in the treatment of the disease. However, cancer remains the second-leading cause of death in the United States, and resistance and toxicity to current treatments hinder progress in fighting the disease. Thus, the search for new treatment strategies with more specificity and less toxicity continues. The ubiquitin-proteasome pathway (UPP) has emerged as a promising target, and metal-based proteasome inhibitory compounds have been investigated as potential treatment strategies.

Citation: Schmitt S, Dou QP (2013) Metal-Based Compounds as Proteasome-Inhibitory Anti-Cancer Drugs. J Pharmacovigilance 1: e101.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger